Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Segro H1 earnings boosted by strong UK rent reviews

(Sharecast News) - Property developer Segro reported a solid set of H1 results on Thursday, with earnings getting a boost from strong UK rent reviews. Segro said adjusted pre-tax profits were up 11% to £252m and earnings per share had risen 6.5% to 18.1p, supported by a 7.8% uplift in like-for-like net rental income.

UK rent reviews delivered a 55% uplift and Segro said it had signed £31m of new headline rent during the period. Completions added £19m of potential rent at a 7.7% yield, with 92% already leased.

Adjusted net asset value per share edged up to 910p, marking the first increase since mid-2022, while Segro's portfolio valuation rose 0.5% to £18.5bn, with rental values up 1.0%.

Looking ahead, Segro noted that its development pipeline remained active, with £50m of potential rent under construction or in advanced negotiations.

The FTSE 100-listed group also declared an interim dividend of 9.7p, up 6.6% year-on-year.

CEO David Sleath said: "Our modern, sustainable portfolio, located in Europe's most attractive and supply-constrained markets, has continued to perform well through the first half of the year, driven by leasing, asset management and the capture of reversion.

"Segro has consistently delivered attractive and compounding increases in both earnings and dividends through the cycle. We are confident in our ability to continue to do this due to the embedded growth potential of our existing portfolio, combined with the potential rent from building out our development pipeline."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.